Publications

Driving clinical research and progress of neurotransformational therapeutics

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Garcia-Romeu, Alan K. Davis, Earth Erowid, Fire Erowid, Roland R. Griffiths, and Matthew W. Johnson. Front. Psychiatry. January 22, 2020

 

Psychedelics in Psychiatry—Keeping the Renaissance From Going Off the Rails

David B. Yaden, PhD, Mary E. Yaden, MD, Roland R. Griffiths, PhD. December 2, 2020

 

Cessation and reduction in alcohol consumption and misuse after psychedelic use

Albert Garcia-Romeu, Alan K Davis, Fire Erowid, Earth Erowid, Roland R Griffiths, Matthew W Johnson. The Journal of Psychopharmacology. May 14, 2019

 

Serotonergic and Dopaminergic Distinctions in the Behavioral Pharmacology of(±)-1-(2,5-Dimethoxy-4-iodophenyl)-2-Aminopropane (DOI) and Lysergic Acid diethylamide (LSD)

Emmanuelle A.D. Schindler, Kuldip D. Dave, Elaine M. Smolock, Vincent J. Aloyo, John A. Harvey. Pharmacology, Biochemistry and Behavior 101 (Mar 2012) 69–76

 

Cholinesterase, Dlysergic Acid Diethylamide, and 2-Bromolysergic Acid Diethylamide

J R BERTINO, G D KLEE, W WEINTRAUB J Clin Exp Psychopathol Q Rev Psychiatry Neurol. Jul-Sep 1959;20:218-22.

 

Role of 5-Hydroxytryptamine in Mental Diseases and its Antagonism to Lysergic Acid Derivatives

A.CERLETTI & E. ROTHLIN  Nature October 22, 1955

Download Our Informative Presentation Here:

Funding Psilocybin to Treat Alcohol Use Disorder